Pathology and new insights in thyroid neoplasms in the 2022 WHO classification

被引:9
|
作者
Lebrun, Laetitia [1 ]
Salmon, Isabelle [1 ,2 ,3 ]
机构
[1] Univ Libre Bruxelles ULB, Erasme Univ Hosp, Hop Univ Bruxelles HUB, CUB Hop Erasme,Dept Pathol, Brussels, Belgium
[2] ULB, Ctr Microscopy & Mol Imaging CMMI, DIAPath, Gosselies, Belgium
[3] Univ Libre Bruxelles ULB, Erasme Univ Hosp HUB, Dept Pathol, Rue Meylemeersch 90, B-1070 Brussels, Belgium
关键词
Bethesda system; fine needle aspiration; molecular testing; screening; thyroid cancer; WHO classification; TERT PROMOTER MUTATIONS; ENCAPSULATED FOLLICULAR VARIANT; INTEROBSERVER VARIABILITY; ASSOCIATION GUIDELINES; GENETIC ALTERATIONS; VASCULAR INVASION; TASK-FORCE; CARCINOMA; CANCER; NODULES;
D O I
10.1097/CCO.0000000000001012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of reviewThe assessment of thyroid nodules is a common clinical problem, linked to the high incidence of thyroid nodules in the population and the low incidence of aggressive thyroid carcinoma. The screening is therefore one of the strengths of our patient care. Recently, the 2023 Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) and 2022 WHO classification of thyroid neoplasms have been released based on the definition of new entities and the growing impact of molecular testing. The aim of this review is to analyze how these upgrades can help us in the daily routine practice diagnosis of thyroid cancer.Recent findingsOur review is focused on the most frequent thyroid tumors derived from thyroid follicular cell. Fine needle aspiration (FNA) is the gold standard for the screening of thyroid nodules with very high levels of sensitivity and specificity. These sensitivity and specificity are improved by molecular testing, which refines the risk of malignancy. The 2023 TBSRTC integrates molecular data and the upgrades integrated in the 2022 WHO classification such as the 'low-risk neoplasms' and the 'high-grade follicular-cells derived carcinoma'. The morphological examination remains crucial since the capsular and/or vascular invasion are key features of malignancy in the follicular thyroid neoplasms. Low-risk neoplasms represent a clinical challenge since no specific guidelines are available. Challenges remain regarding oncocytic thyroid lesions, which are not associated with specific diagnostic molecular biomarkers. Molecular testing can help not only in deciphering the prognosis but also in the targeted therapeutic strategy.SummaryWhile molecular testing has succeeded to substantially improve the pre and postoperative diagnosis and risk stratification of thyroid tumors, the morphological examination is still central in the daily routine diagnosis of thyroid pathology. Future is the integrated diagnosis of clinical, morphological, molecular and epigenetic features with the help of artificial intelligence algorithms.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 50 条
  • [1] Overview of the 2022 WHO Classification of Thyroid Neoplasms
    Baloch, Zubair W.
    Asa, Sylvia L.
    Barletta, Justine A.
    Ghossein, Ronald A.
    Juhlin, C. Christofer
    Jung, Chan Kwon
    LiVolsi, Virginia A.
    Papotti, Mauro G.
    Sobrinho-Simoes, Manuel
    Tallini, Giovanni
    Mete, Ozgur
    ENDOCRINE PATHOLOGY, 2022, 33 (01) : 27 - 63
  • [2] Novelties of the 2022 WHO classification of thyroid neoplasms
    Guyetant, Serge
    Petrucci, Myriam Decaussin
    Leteurtre, Emmanuelle
    ANNALES DE PATHOLOGIE, 2024, 44 (01) : 5 - 19
  • [3] Overview of the 2022 WHO Classification of Thyroid Neoplasms
    Zubair W. Baloch
    Sylvia L. Asa
    Justine A. Barletta
    Ronald A. Ghossein
    C. Christofer Juhlin
    Chan Kwon Jung
    Virginia A. LiVolsi
    Mauro G. Papotti
    Manuel Sobrinho-Simões
    Giovanni Tallini
    Ozgur Mete
    Endocrine Pathology, 2022, 33 : 27 - 63
  • [4] The Impact of the 2022 WHO Classification of Thyroid Neoplasms on Everyday Practice of Cytopathology
    Esther Diana Rossi
    Zubair Baloch
    Endocrine Pathology, 2023, 34 : 23 - 33
  • [5] The Impact of the 2022 WHO Classification of Thyroid Neoplasms on Everyday Practice of Cytopathology
    Rossi, Esther Diana
    Baloch, Zubair
    ENDOCRINE PATHOLOGY, 2023, 34 (01) : 23 - 33
  • [6] New WHO classification of thyroid tumors: a pragmatic categorization of thyroid gland neoplasms
    Manuel Cameselle-Teijeiro, Jose
    Sobrinho-Simoes, Manuel
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2018, 65 (03): : 133 - 135
  • [7] Comparison of ultrasound findings of papillary thyroid carcinoma subtypes based on the 2022 WHO classification of thyroid neoplasms
    Hekimsoy, Ilhan
    Ertan, Yesim
    Serin, Gurdeniz
    Karabulut, Ahmet Kasim
    Ozbek, Suha Sureyya
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [8] Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
    Rindi, Guido
    Mete, Ozgur
    Uccella, Silvia
    Basturk, Olca
    La Rosa, Stefano
    Brosens, Lodewijk A. A.
    Ezzat, Shereen
    de Herder, Wouter W.
    Klimstra, David S.
    Papotti, Mauro
    Asa, Sylvia L.
    ENDOCRINE PATHOLOGY, 2022, 33 (01) : 115 - 154
  • [9] Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
    Guido Rindi
    Ozgur Mete
    Silvia Uccella
    Olca Basturk
    Stefano La Rosa
    Lodewijk A. A. Brosens
    Shereen Ezzat
    Wouter W. de Herder
    David S. Klimstra
    Mauro Papotti
    Sylvia L. Asa
    Endocrine Pathology, 2022, 33 : 115 - 154
  • [10] WHO classification 2022 of chronic myeloproliferative neoplasms
    Hochhaus, Andreas
    Ott, German
    Siebert, Reiner
    ONKOLOGIE, 2023, 29 (04): : 287 - 295